Sharieff Khavir A, Duncan David, Younossi Zobair
Inova Transplant Center at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA.
Cleve Clin J Med. 2002 Feb;69(2):155-9. doi: 10.3949/ccjm.69.2.155.
New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial.
聚乙二醇化干扰素联合利巴韦林的新治疗方案可使超过50%的慢性丙型肝炎病例产生持续病毒学应答。相比之下，直到最近仍是标准治疗方法的普通干扰素α与利巴韦林联合使用，仅能使35%至40%的病例产生持续病毒学应答。随着新治疗方案疗效的提高，采取额外措施妥善处理其副作用并最大程度提高依从性可能变得至关重要。
